Search results for "ORPHAN DRUG|Designated|Treatment of Stage IIb through Stage IV BRAF mutant melanoma" in comments (approximate match)
Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
BVD-523 potently and selectively inhibits ERK1 and ERK2 kinases in a reversible, ATP-competitive fashion. Consistent with its mechanism of action, BVD-523 inhibits signal transduction, cell proliferation, and cell survival, most potently in cell line...